Reach Us +44-2036084181
Advances In QSAR Studies On Calcium Channel Blockers | 7923
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

26th World Cardiology Conference

Bangkok, Thailand

2nd World Cardiology Experts Meeting

Sydney, Australia
Share This Page

Advances in QSAR Studies on Calcium channel blockers

International Conference & Exhibition on Clinical Research Dermatology, Ophthalmology & Cardiology

Satya P. Gupta

ScientificTracks Abstracts: JCEC

DOI: 10.4172/2155-9880.S1.01

Calcium channel blockers (CCBs) have got potential therapeutic uses against several cardiovascular and non-cardiovascular diseases, such as angina, hypertension, arrhythmias, sthma, dysmenorrhea, premature labor, cancer, epilepsy, glaucoma, etc. The three principia structural classes of compounds have been found to act as potent calcium channel blockers and they are phenylalkylamines, 1,4-dihydropyridines (DHPs), and benzodiazepines. Recently, a few more classes of CCBs have been studied. All these classes of CCBs have been found to be the most effective drugs against vasospastic angina. These drugs selectively inhibit Ca2+ influx into heart muscles by blocking slow inward channels for Ca2+ or inhibit Ca2+ influx into vascular smooth muscles. The result is negative inotropism of smooth muscle relaxation, which is translated into hypotension. We intend to present a comprehensive review, including the most recent studies, on quantitative structure-activity relationship (QSAR) and molecular modelling studies on all kinds of CCBs. These studies lead to highlight the essential structural features and physicochemical properties that the compounds should possess to act as potentia l CCBs. These studies also describe vividly the mechanism of interaction of CCBs with the calcium channel.
After his doctorate, in 1973 from the University of Allahabad, Dr. Gupta spent a couple of years at Tata Institute of Fundament al Research (TIFR), Mumbai, working on the structure and functions of bio membranes. In 1973, he joined Birla Institute of Technology and Science ( BITS), Pilani, from where he recently moved to Meerut Institute of Engineering and Technology ( MIET), Meerut. Since long he has been working on th e theoretical aspects of drug design. He has made notable contributions in this area, for which he has been bestowed upon, in 1990, the Ranba xy Research Foundation Award, a coveted national award, and made, in 1985, the Fellow of the National Academy of Sciences, India (F.N. A. S c.). He has been an advisory member of the Technical Resource Group on Research and Development on HIV/AIDS, constituted by Ministry of Health a nd Welfare, Government of India. Dr. Gupta is has been the Editor-in- Chief of four international journals, namely Cardiovascular and Haema tological Agents in Medicinal Chemistry, Current Computer-Aided Drug Design, Current Enzyme Inhibition, and Current Bioinformatics, all published b y the Bentham Science Publishers BV, The Netherlands and U.S.A. He has also acted as a guest editor of a few prestigious international journa ls and recently guest-edited two volumes of Topics in Heterocyclic Drugs